Law360, New York (May 22, 2012, 6:14 PM EDT) -- On May 7, 2012, the U.S. Department of Justice (DOJ) announced that Abbott Laboratories pleaded guilty to a misdemeanor under the Food, Drug and Cosmetic Act and agreed to pay $1.5 billion to resolve criminal and civil liability relating to allegations of off-label promotion of the prescription drug Depakote.
Abbott also entered into a five-year Corporate Integrity Agreement (CIA) with the Office of Inspector General of the U.S. Department of Health and Human Services (HHS-OIG).
These components of Abbott’s settlement have become relatively standard in DOJ...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.